A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2019
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY HoFH
- Sponsors Regeneron Pharmaceuticals
- 05 Sep 2018 Planned End Date changed from 18 Jun 2019 to 17 Jun 2019.
- 05 Sep 2018 Planned primary completion date changed from 23 Jan 2019 to 10 Jan 2019.
- 31 Aug 2018 Biomarkers information updated